Literature DB >> 16210694

Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.

Georgios T Stathopoulos1, Zhiwen Zhu, M Brett Everhart, Ioannis Kalomenidis, William E Lawson, Semra Bilaceroglu, Todd E Peterson, Daphne Mitchell, Fiona E Yull, Richard W Light, Timothy S Blackwell.   

Abstract

We developed a novel mouse model of malignant pleural effusion (MPE) by injecting Lewis lung cancer (LLC) cells directly into the pleural space of syngeneic C57B/6 mice. The pleural effusions in this model share common cellular and biochemical features with human MPEs. Implantation and growth of pleural tumors triggers a host inflammatory response characterized by a mixed inflammatory cell influx into the pleural fluid. LLC cells exhibited high basal nuclear factor (NF)-kappaB activity in vitro and in vivo, which we used to drive expression of a NF-kappaB-dependent green fluorescent protein-firefly luciferase fusion reporter construct. NF-kappaB-dependent reporter expression allowed intravital tracing of pleural tumors. Inhibition of NF-kappaB in LLC cells did not affect cell viability in culture; however, injection of LLC cells expressing a dominant NF-kappaB inhibitor resulted in decreased tumor burden, decreased pleural effusion volume, and decreased pleural effusion TNF-alpha levels. These studies indicate that tumor NF-kappaB activity regulates pleural tumor progression. This reproducible model of MPE can be used to further study the influence of specific host and tumor factors on the pathogenesis of MPE and evaluate new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210694      PMCID: PMC2644178          DOI: 10.1165/rcmb.2005-0130OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  39 in total

1.  Association of cancer with AIDS-related immunosuppression in adults.

Authors:  M Frisch; R J Biggar; E A Engels; J J Goedert
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

Authors:  S Yano; R S Herbst; H Shinohara; B Knighton; C D Bucana; J J Killion; J Wood; I J Fidler
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

3.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

4.  Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis.

Authors:  S Huang; C A Pettaway; H Uehara; C D Bucana; I J Fidler
Journal:  Oncogene       Date:  2001-07-12       Impact factor: 9.867

5.  Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro.

Authors:  S A Milligan; C Nopajaroonsri
Journal:  Anticancer Res       Date:  2001 Jan-Feb       Impact factor: 2.480

6.  Cancer incidence in New York State acquired immunodeficiency syndrome patients.

Authors:  B Gallagher; Z Wang; M J Schymura; A Kahn; E J Fordyce
Journal:  Am J Epidemiol       Date:  2001-09-15       Impact factor: 4.897

7.  High-dose dexamethasone accentuates nuclear factor-kappa b activation in endotoxin-treated mice.

Authors:  R T Sadikot; E D Jansen; T R Blackwell; O Zoia; F Yull; J W Christman; T S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2001-09-01       Impact factor: 21.405

8.  Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12.

Authors:  Y Sugiyama; M Kato; F A Chen; S S Williams; Y Kawaguchi; K Miya; Y S Jong; E Mathiowitz; N K Egilmez; R B Bankert
Journal:  J Immunother       Date:  2001 Jan-Feb       Impact factor: 4.456

9.  Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8.

Authors:  S Huang; J B Robinson; A Deguzman; C D Bucana; I J Fidler
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

10.  Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion.

Authors:  Judith H Harmey; Corazon D Bucana; Weixin Lu; Anne Marie Byrne; Susan McDonnell; Conor Lynch; David Bouchier-Hayes; Zhongyun Dong
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

View more
  38 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.

Authors:  Sophia P Karabela; Ioannis Psallidas; Taylor P Sherrill; Chrysoula A Kairi; Rinat Zaynagetdinov; Dong-Sheng Cheng; Spyridoula Vassiliou; Frank McMahon; Linda A Gleaves; Wei Han; Ioannis Stathopoulos; Spyros G Zakynthinos; Fiona E Yull; Charis Roussos; Ioannis Kalomenidis; Timothy S Blackwell; Georgios T Stathopoulos
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

Review 3.  Bioluminescence imaging.

Authors:  Ruxana T Sadikot; Timothy S Blackwell
Journal:  Proc Am Thorac Soc       Date:  2005

Review 4.  Pleural involvement in lung cancer.

Authors:  Theodora Agalioti; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

5.  Malignant pleural effusion: further translational research is crucial.

Authors:  Yasuhiko Nishioka
Journal:  Transl Lung Cancer Res       Date:  2012-09

6.  Establishment of a malignant pleural effusion mouse model: pathogenesis pathways.

Authors:  Kalliopi Domvri; Paul Zarogoulidis; Fotis Theodoropoulos; Haidong Huang; Konstantinos Zarogoulidis
Journal:  Transl Lung Cancer Res       Date:  2012-09

7.  Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Taylor P Sherrill; Sophia P Karabela; Kasia Goleniewska; Ioannis Kalomenidis; Charis Roussos; Barbara Fingleton; Fiona E Yull; R Stokes Peebles; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2010-07-01       Impact factor: 21.405

8.  Mast cells mediate malignant pleural effusion formation.

Authors:  Anastasios D Giannou; Antonia Marazioti; Magda Spella; Nikolaos I Kanellakis; Hara Apostolopoulou; Ioannis Psallidas; Zeljko M Prijovich; Malamati Vreka; Dimitra E Zazara; Ioannis Lilis; Vassilios Papaleonidopoulos; Chrysoula A Kairi; Alexandra L Patmanidi; Ioanna Giopanou; Nikolitsa Spiropoulou; Vaggelis Harokopos; Vassilis Aidinis; Dionisios Spyratos; Stamatia Teliousi; Helen Papadaki; Stavros Taraviras; Linda A Snyder; Oliver Eickelberg; Dimitrios Kardamakis; Yoichiro Iwakura; Thorsten B Feyerabend; Hans-Reimer Rodewald; Ioannis Kalomenidis; Timothy S Blackwell; Theodora Agalioti; Georgios T Stathopoulos
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

9.  Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion.

Authors:  Fang Fang; Ping Chen; Xin Wu; Li Yang; Xun Yang; Zhen-Xiang Xi; Bin-Wen Zhou; Xi-Kun Zhou; Zhi-Yong Qian; Bo Xiao; Yu-Quan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-15       Impact factor: 4.553

10.  Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

Authors:  Ioannis Psallidas; Sophia P Karabela; Charalampos Moschos; Taylor P Sherrill; Androniki Kollintza; Sophia Magkouta; Panagiota Theodoropoulou; Charis Roussos; Timothy S Blackwell; Ioannis Kalomenidis; Georgios T Stathopoulos
Journal:  Mol Cancer       Date:  2010-03-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.